Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

zorifertinib (AZD3759)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Alpha Biopharma, AstraZeneca

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

furmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	AZD3759 Sensitive: B - Late Trials AZD3759 Sensitive : B	AZD3759 Sensitive: B - Late Trials AZD3759 Sensitive : B
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	AZD3759 Sensitive: C3 – Early Trials AZD3759 Sensitive : C3	AZD3759 Sensitive: C3 – Early Trials AZD3759 Sensitive : C3
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	AZD3759 Sensitive: C3 – Early Trials AZD3759 Sensitive : C3	AZD3759 Sensitive: C3 – Early Trials AZD3759 Sensitive : C3